Search

everythinglearnresearchcommunity

for

Search:↓

Early adrenal gland maturation in young children can be normal, but other serious conditions should be ruled out first.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.

Hormone therapies like birth control pills and spironolactone are safe and effective for treating women's adult acne.

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

Most hirsutism cases are due to PCOS, and treatment focuses on lowering testosterone and blocking its effects.

The conclusion suggests that PCOS may persist due to genetic traits that, while harmful for female fertility, could have provided survival and reproductive benefits to males.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Adrenal gland disease is common in ferrets and causes hair loss and other symptoms.

Effective hirsutism management requires identifying the cause, combining new and traditional treatments, and setting realistic expectations for patients.

Finasteride exposure harms tadpole reproduction and hormone balance.

New treatments for skin conditions related to the sebaceous gland are being developed based on current research.

Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.

Parathyroid hormones are important for hair growth, but their use in treating hair loss from chemotherapy is still uncertain.

Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.

Testosterone significantly affects sexual desire in both men and women, but its impact on women is more complex and influenced by psychological factors.

Hirsutism is too much hair growth in women like the pattern in men, often caused by high male hormones, and can be treated with hormone control and hair removal methods.

A combination of nanomilled oral testosterone and dutasteride normalized testosterone levels in men with low testosterone and is safe for short-term use.

Pregnancy with Cushing's syndrome is rare and risky for both mother and baby, needing early diagnosis and treatment.

LGR5 and LGR6 are expressed differently in various skin tumors, which may offer clues about their origins.

The document concludes that managing female hyperandrogenism requires a combination of identifying the cause, lifestyle changes, medication, and cosmetic treatments.

The document concludes that treating androgen excess needs patience, managing expectations is important, and many drugs used are not officially approved, suggesting cosmetic options for mild cases.

Finasteride negatively affects fish reproduction and gonadal development.

Most women with hirsutism have it because of PCOS, and they need long-term treatment including medication and hair removal to improve their condition.

Hair loss led to the diagnosis of Cushing's disease in a patient, showing that hair loss can be a sign of hormonal disorders.

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

Older patients with Cushing's syndrome often have different symptoms and treatment outcomes compared to younger patients.

5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.